A core GlaxoSmithKline R&D executive said the company expects the number of anti-cancer drug candidates in clinical trials to almost double next year, highlighting that a series of acquisitions are rapidly enriching its new drug pipeline. Hersham Abdullah, head of oncology research and development at the British pharmaceutical company, said in an interview that the company is making every effort to speed up and return to the oncology drug circuit. “Currently, we have 5 approved anti-cancer drugs, which will probably increase to 6 in a few weeks. We currently have around 15 clinical-stage oncology assets, and we expect this size to nearly double by 2027.” Following the implementation of a series of mergers and acquisitions, the GlaxoSmithKline oncology pipeline now covers hematomas, lung cancer, gynecologic cancer, gastrointestinal tumors, and prostate cancer; there are many types of drugs, including antibody drug conjugates, immunotherapy that mobilizes the immune system to kill tumors, and next-generation small-molecule drugs. Abdullah said, “The incidence of cancer among multiple patient groups continues to rise. We chose to return to the oncology circuit. One of the core motivations is to meet huge unmet clinical needs.” However, Royal Bank of Canada capital market analysts suggested in the research report that although the oncology business is set as a strategic priority, related products are not expected to contribute significant revenue until around the end of 2029; at the same time, GlaxoSmithKline's AIDS ace business is about to face generic drug competition.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.